Related Experiment Videos
[Treatment of Kawasaki's syndrome with high dose intravenous gammaglobulins]
Insights
High-dose intravenous gammaglobulin therapy, alongside salicylate, shows promise in preventing coronary artery aneurysms in children with Kawasaki disease. This treatment approach appears effective in reducing serious cardiac complications.
Area of Science:
- Pediatric Cardiology
- Immunology
Background:
- Kawasaki disease poses a significant risk due to potential coronary artery aneurysm formation.
- Preventing cardiac complications is a primary goal in managing Kawasaki disease.
Observation:
- Two pediatric patients with Kawasaki disease were treated with salicylate and high-dose intravenous immunoglobulin (IVIG).
- Treatment was administered analogous to protocols for idiopathic thrombocytopenic purpura.
Findings:
- Clinical, electrocardiographic, radiological, and echocardiographic monitoring revealed no signs of coronary aneurysms for over six months post-treatment.
- High-dose IVIG, supported by prior research (Furusho's study), appears to decrease the incidence of coronary aneurysms in Kawasaki syndrome patients.
Implications:
- High-dose IVIG may be a crucial therapeutic strategy for mitigating severe cardiac sequelae in Kawasaki disease.
- Further research into IVIG's role in Kawasaki disease management is warranted to confirm these findings and optimize treatment protocols.
Abstract:
The apparition of coronary aneurysms in Kawasaki syndrome is the reason for the serious nature of this disease. Many attempts have been made to prevent this complication. Two children, respectively 10 and 28 months old, were treated in our unit with salicylate and high dose intravenous gammaglobulin by analogy with the treatment of idiopathic thrombocytopenic purpura. The clinical, electrical, radiological, echographic cardiac surveillance did not show any sign of aneurysms more than 6 months after the onset of the disease. Following the Furusho's study, high dose intravenous gammaglobulin seems to reduce the frequency of coronary aneurysms in patients with Kawasaki syndrome.